A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia

被引：34

作者：

Cirmena, Gabriella ^{[1
]}

Aliano, Stefania ^{[1
]}

Fugazza, Giuseppina ^{[1
]}

Bruzzone, Roberto ^{[1
]}

Garuti, Anna ^{[1
]}

Bocciardi, Renata ^{[2
]}

Bacigalupo, Andrea ^{[1
]}

Ravazzolo, Roberto ^{[2
]}

Ballestrero, Alberto ^{[1
]}

Sessarego, Mario ^{[1
]}

机构：

[1] Univ Genoa, Dept Hematol, I-16132 Genoa, Italy

[2] G Gaslini Inst Children, Mol Genet Lab, Genoa, Italy

来源：

CANCER GENETICS AND CYTOGENETICS | 2008年 / 183卷 / 02期

关键词：

D O I：

10.1016/j.cancergencyto.2008.02.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report the occurrence of a BCR-JAK2 fusion gene in a case of acute myeloid leukemia (AML) resulting from a t(9;22)(p24;q11) translocation as the sole cytogenetic abnormality. The BCR-JAK2 fusion gene has the same breakpoint in BCR as is found in the BCR/ABL p210. The chimeric gene is the result of a reciprocal translocation between chromosomes 9 and 22, which implies a double break on chromosome 9; this has allowed generating an in-frame fusion transcript. Previously, BCR-JAK2 rearrangement was observed in a single case with atypical chronic myelogenous leukemia (CML), but in that case the breakpoint in the BCR was different. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：105 / 108

页数：4

共 9 条

[1]

Ballestrero A, 2001, CANCER-AM CANCER SOC, V92, P2030, DOI 10.1002/1097-0142(20011015)92:8<2030::AID-CNCR1541>3.0.CO

[2]

2-G

[3] Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program [J].

Gabert, J ;

Beillard, E ;

van der Velden, VHJ ;

Bi, W ;

Grimwade, D ;

Pallisgaard, N ;

Barbany, G ;

Cazzaniga, G ;

Cayuela, JM ;

Cavé, H ;

Pane, F ;

Aerts, JLE ;

De Micheli, D ;

Thirion, X ;

Pradel, V ;

González, M ;

Viehmann, S ;

Malec, M ;

Saglio, G ;

van Dongen, JJM .

LEUKEMIA, 2003, 17 (12) :2318-2357

[4] The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients [J].

Goerttler, PS ;

Steimle, C ;

März, E ;

Johansson, PL ;

Andreasson, B ;

Griesshammer, M ;

Gisslinger, H ;

Heimpel, H ;

Pahl, HL .

BLOOD, 2005, 106 (08) :2862-2864

[5] A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q 11.2) translocation in a patient with a clinically typical chronic myeloid leukemia [J].

Griesinger, F ;

Hennig, H ;

Hillmer, F ;

Podleschny, M ;

Steffens, R ;

Pies, A ;

Wörmann, B ;

Haase, D ;

Bohlander, SK .

GENES CHROMOSOMES & CANCER, 2005, 44 (03) :329-333

[6] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].

Kralovics, R ;

Passamonti, F ;

Buser, AS ;

Teo, S ;

Tiedt, R ;

Passweg, JR ;

Tichelli, A ;

Cazzola, M ;

Skoda, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790

[7] A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia [J].

Lacronique, V ;

Boureux, A ;

DellaValle, V ;

Poirel, H ;

Quang, CT ;

Mauchauffe, M ;

Berthou, C ;

Lessard, M ;

Berger, R ;

Ghysdael, J ;

Bernard, OA .

SCIENCE, 1997, 278 (5341) :1309-1312

[8] The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2 [J].

Reiter, A ;

Walz, C ;

Watmore, A ;

Schoch, C ;

Blau, I ;

Schlegelberger, B ;

Berger, U ;

Telford, N ;

Aruliah, S ;

Yin, JA ;

Vanstraelen, D ;

Barker, HF ;

Taylor, PC ;

O'Driscoll, A ;

Benedetti, F ;

Rudolph, C ;

Kolb, HJ ;

Hochhaus, A ;

Hehlmann, R ;

Chase, A ;

Cross, NCP .

CANCER RESEARCH, 2005, 65 (07) :2662-2667

[9] Neutrophilic-chronic myeloid leukemia - Low levels of p230 BCR/ABL mRNA and undetectable p230 BCR/ABL protein may predict an indolent course [J].

Verstovsek, S ;

Lin, H ;

Kantarjian, H ;

Saglio, G ;

De Micheli, D ;

Pane, F ;

Garcia-Manero, G ;

Intrieri, M ;

Rotoli, B ;

Salvatore, F ;

Guo, JQ ;

Talpaz, M ;

Specchia, G ;

Pizzolo, G ;

Liberati, AM ;

Cortes, J ;

Quackenbush, RC ;

Arlinghaus, RB .

CANCER, 2002, 94 (09) :2416-2425

← 1 →